trials of combination immuno-radiation for unresectable hepatocellular carcinoma.
作者信息
Mendiratta-Lala Mishal, El Naqa Issam, Owen Dawn
机构信息
Department of Radiology, University of Michigan, Ann Arbor, Michigan, USA.
Machine Learning Department, Moffitt Cancer Center, Tampa, Florida, USA.
出版信息
Transl Cancer Res. 2023 Apr 28;12(4):709-712. doi: 10.21037/tcr-22-2906. Epub 2023 Mar 31.
Abstract
摘要
相似文献
1
trials of combination immuno-radiation for unresectable hepatocellular carcinoma.不可切除肝细胞癌联合免疫放疗的试验
Transl Cancer Res. 2023 Apr 28;12(4):709-712. doi: 10.21037/tcr-22-2906. Epub 2023 Mar 31.
2
Role of External Beam Radiotherapy in Hepatocellular Carcinoma.外照射放疗在肝细胞癌中的作用。
Clin Liver Dis. 2020 Nov;24(4):701-717. doi: 10.1016/j.cld.2020.07.006. Epub 2020 Sep 2.
3
The Degree of Lipiodol Accumulation Can Be an Indicator of Successful Treatment for Unresectable Hepatocellular Carcinoma (HCC) Patients - in the Case of Transcatheter Arterial Chemoembolization (TACE) and External Beam Radiotherapy (EBRT).碘油蓄积程度可作为不可切除肝细胞癌（HCC）患者治疗成功的指标——以经动脉化疗栓塞术（TACE）和外照射放疗（EBRT）为例。
J Cancer. 2016 Jul 4;7(11):1413-20. doi: 10.7150/jca.15405. eCollection 2016.
4
Does external beam radiation therapy improve survival following transarterial chemoembolization for unresectable hepatocellular carcinoma?对于不可切除的肝细胞癌，外照射放疗会提高经动脉化疗栓塞后的生存率吗？
Gastrointest Cancer Res. 2012 Jan;5(1):13-7.
5
Recent clinical applications of external beam radiotherapy for hepatocellular carcinoma according to guidelines, major trials and meta-analyses.根据指南、主要试验和荟萃分析，近期肝细胞癌外照射放疗的临床应用
J Med Imaging Radiat Oncol. 2019 Dec;63(6):812-821. doi: 10.1111/1754-9485.12948. Epub 2019 Sep 3.
6
Efficacy and safety of external-beam radiation therapy for hepatocellular carcinoma: An overview of current evidence according to the different target population.外照射治疗肝细胞癌的疗效和安全性：根据不同目标人群的当前证据概述。
Biosci Trends. 2019 Mar 14;13(1):10-22. doi: 10.5582/bst.2018.01261. Epub 2019 Feb 24.
7
Comparison between radioimmunotherapy and external beam radiation therapy for patients with hepatocellular carcinoma.肝细胞癌患者放射性免疫疗法与外照射放疗的比较。
Eur J Nucl Med Mol Imaging. 2002 Dec;29(12):1657-68. doi: 10.1007/s00259-002-0996-x. Epub 2002 Oct 3.
8
Is it time to adopt external beam radiotherapy in the NCCN guidelines as a therapeutic strategy for intermediate/advanced hepatocellular carcinoma?在 NCCN 指南中，是否是时候将外部束放射治疗作为中/晚期肝细胞癌的治疗策略了？
Oncology. 2013;84 Suppl 1:69-74. doi: 10.1159/000345893. Epub 2013 Feb 20.
9
Low Utilization of External Beam Radiation Therapy for Patients With Unresectable Hepatocellular Carcinoma: An Analysis of the United Network for Organ Sharing Database.不可切除肝细胞癌患者外照射放疗的低利用率：器官共享联合网络数据库分析
Int J Radiat Oncol Biol Phys. 2022 Oct 1;114(2):231-237. doi: 10.1016/j.ijrobp.2022.05.028. Epub 2022 May 30.
10
Systematic review of adjuvant external beam radiotherapy for hepatocellular carcinoma following radical hepatectomy.根治性肝切除术后辅助外照射放疗治疗肝细胞癌的系统评价。
Radiother Oncol. 2022 Oct;175:101-111. doi: 10.1016/j.radonc.2022.08.019. Epub 2022 Aug 22.
本文引用的文献
1
Radiomics to evaluate interlesion heterogeneity and to predict lesion response and patient outcomes using a validated signature of CD8 cells in advanced melanoma patients treated with anti-PD1 immunotherapy.利用抗 PD-1 免疫治疗的晚期黑色素瘤患者中 CD8 细胞的验证特征，通过放射组学评估病变间异质性并预测病变反应和患者结局。
J Immunother Cancer. 2022 Oct;10(10). doi: 10.1136/jitc-2022-004867.
2
Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis.免疫检查点抑制剂联合治疗的益处及肿瘤突变负担在肝细胞癌中的预测作用：系统评价和荟萃分析。
Int Immunopharmacol. 2022 Nov;112:109244. doi: 10.1016/j.intimp.2022.109244. Epub 2022 Sep 18.
3
Phase 1 Randomized Trial of Stereotactic Body Radiation Therapy Followed by Nivolumab plus Ipilimumab or Nivolumab Alone in Advanced/Unresectable Hepatocellular Carcinoma.立体定向体部放疗序贯纳武利尤单抗联合伊匹单抗或纳武利尤单抗治疗不可切除/晚期肝细胞癌的 1 期随机试验。
Int J Radiat Oncol Biol Phys. 2023 Jan 1;115(1):202-213. doi: 10.1016/j.ijrobp.2022.09.052. Epub 2022 Sep 13.
4
Combination Transarterial Chemoembolization and Stereotactic Body Radiation Therapy for Unresectable Single Large Hepatocellular Carcinoma: Results From a Prospective Phase 2 Trial.联合经动脉化疗栓塞和立体定向体部放疗治疗不可切除的单发大肝癌：一项前瞻性 2 期试验结果。
Int J Radiat Oncol Biol Phys. 2022 Oct 1;114(2):221-230. doi: 10.1016/j.ijrobp.2022.05.021. Epub 2022 May 26.
5
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.纳武利尤单抗对比索拉非尼用于治疗晚期肝细胞癌（CheckMate 459）：一项随机、多中心、开放标签、III 期临床试验。
Lancet Oncol. 2022 Jan;23(1):77-90. doi: 10.1016/S1470-2045(21)00604-5. Epub 2021 Dec 13.
6
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma.美国癌症免疫治疗学会（SITC）肝癌治疗免疫治疗临床实践指南。
J Immunother Cancer. 2021 Sep;9(9). doi: 10.1136/jitc-2021-002794.
7
Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study.替西木单抗联合度伐利尤单抗治疗不可切除肝细胞癌患者的安全性、疗效和药效学：一项 I/II 期研究的随机扩展。
J Clin Oncol. 2021 Sep 20;39(27):2991-3001. doi: 10.1200/JCO.20.03555. Epub 2021 Jul 22.
8
A deep survival interpretable radiomics model of hepatocellular carcinoma patients.肝细胞癌患者深度生存可解释放射组学模型。
Phys Med. 2021 Feb;82:295-305. doi: 10.1016/j.ejmp.2021.02.013. Epub 2021 Mar 10.
9
Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC).durvalumab 治疗不可切除 III 期非小细胞肺癌（PACIFIC）患者的既往放化疗相关变量对结局的影响。
Lung Cancer. 2021 Jan;151:30-38. doi: 10.1016/j.lungcan.2020.11.024. Epub 2020 Nov 26.
10
Rural-Urban Geographical Disparities in Hepatocellular Carcinoma Incidence Among US Adults, 2004-2017.美国成年人 2004-2017 年肝癌发病率的城乡地理差异。
Am J Gastroenterol. 2021 Feb 1;116(2):401-406. doi: 10.14309/ajg.0000000000000948.
Zotero 插件